Future studies comparing the metabolic fingerprints of the HGSOC cell lines with those of patient-derived cancer cells and devising methodologies for the targeted delivery of GABA, Glu, and 5-HT antagonists to ovarian cancer tissue should pave the way for novel metabolic fingerprinting-based targeted therapy in ovarian cancer. This evidence concerns the gene HTR5A and cancer.